Gene therapy for chronic peripheral arterial disease: what role for the vascular surgeon?
The incidence of peripheral arterial disease is rising and despite advances in clinical management, many problems remain unsolved. Better knowledge of the mechanisms and consequences associated with chronic muscle ischemia has opened the way for development of new treatment strategies, including therapeutic angiogenesis. Therapeutic angiogenesis is a promising technique based on experimental studies showing that growth factors or genes able to increase capillary density can be used to reduce the impact of muscle ischemia and increase blood flow to ischemic tissue. Enthusiasm for this technique has prompted numerous clinical trials with encouraging results, but data are still inconclusive. Optimal indications for gene therapy must be defined and further experimental progress is needed to respond to ethical issues. Therapeutic angiogenesis should be viewed as an adjunct to rather than as a competitor of current surgical revascularization techniques.
Barandon
Laurent
L
Department of Cardiovascular Surgery, Haut-Leveque Hospital, Pessac, France. lesbarandon@wanadoo.fr
Leroux
Lionel
L
Dufourcq
Pascale
P
Plagnol
Philippe
P
Deville
Claude
C
Duplaa
Cécile
C
Couffinhal
Thierry
T
D002908:Chronic Disease; D005346:Fibroblast Growth Factors / Q000502:physiology; D018014:Gene Transfer Techniques; D013502:General Surgery; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D007511:Ischemia / Q000503:physiopathology*; D018482:Muscle, Skeletal / Q000098:blood supply*; D018919:Neovascularization, Physiologic; D010819:Physician's Role; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000502:physiology
D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors